Ligand spin-out spies share of growing antibody discovery market

24 March 2022

In the latest in a series of life sciences SPAC mergers, Ligand Pharmaceuticals (Nasdaq: LGND) is to use the approach to hive off its antibody business.

The company’s antibody discovery biotech, OmniAb, will be spun-out and then immediately merged with a newly-formed subsidiary of Avista Public Acquisition Corp II (APAC), a blank check company.

APAC, a private equity firm focused on the healthcare industry, will invest up to $115 million in the combined company, whereas Ligand will contribute $15 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK